This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
Generated Narrative: ArtifactAssessment
Resource ArtifactAssessment "179698" Version "4" Updated "2023-12-06 08:41:24+0000"
Profile: Adaptation
Artifact Author: Joanne Dehnbostel:
Artifact URL: https://fevir.net/resources/ArtifactAssessment/179698
Artifact Description: This example of an Adaptation Profile shows the specific content that was changed when adapting one Recommendation Profile instance to create a new Recommendation Profile instance, serving a role of 'track changes' for structured data.
modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]
identifier: FEvIR Object Identifier: 179698
title: Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
artifact: Composition/179466: Recommendation: ADA Obesity Management Recommendation 8.16
content
informationType: container
type: adapted element ()
classifier: string Datatype (Evidence Based Medicine on FHIR Implementation Guide Code System#string-datatype)
path:
overallSummary
Components
InformationType Summary Type Classifier comment 8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A Original Resource Content (Evidence Based Medicine on FHIR Implementation Guide Code System#OriginalResourceContent) response Rationale for Change to Resource Content (Evidence Based Medicine on FHIR Implementation Guide Code System#RationaleForChange) Suggested change (Evidence Based Medicine on FHIR Implementation Guide Code System#suggested-change) change-request 8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. Suggested Change to Resource Content (Evidence Based Medicine on FHIR Implementation Guide Code System#SuggestedChange)